The United Kingdom’s National Institute for Health and Care Excellence (NICE) has chosen to not recommend the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for use in treatment-naïve adult patients with advanced renal cell carcinoma (RCC).1
“Overall, an option that improved survival and reduced [AEs] would be welcomed by patients and clinicians to allow more choice of treatment and individualized care plans,” the committee concluded.
- Appraisal consultation document: pembrolizumab with axitinib for untreated advanced renal cell carcinoma. National Institute for Health and Care Excellence. Published February 2020. bit.ly/2HuQhy5. Accessed February 12, 2020.
- Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116-1127. doi: 10.1056/NEJMoa1816714.
... to read the full story